Goodwin’s Life Sciences team represented Dimension Therapeutics, Inc. in its agreement to be acquired by REGENXBIO Inc. in all-stock transaction for an implied value of approximately $3.41 per share at a 150% premium. The boards of directors of both companies have unanimously approved the transaction.

It is anticipated that the transaction will close by year-end 2017, subject to approval by Dimension shareholders, receipt of any required customary regulatory approvals and the satisfaction of other customary closing conditions.

For additional details on the transaction, please read the press release.

The Goodwin team was led by partners Kingsley Taft and Andrew Goodman and included partners Caitlin Murray and James Matarese, Tobias Schad, Catherine Magazu and Andre Garron (Life Sciences); partner Brian Fairchild, counsel Kathleen Kean and associate Noelle Dubiansky (Intellectual Property); partner Janet Andolina and associate Todd Pollock (Tax);  partners Scott Webster and Natascha George and associate Megan Juel (ERISA); partner Scott Lassman (FDA Regulation); partner Jennifer Fay and associate Christina Bitter (Labor and Employment); partner Andrea Murino and Todd Hahn (Antitrust); counsel Jacqueline Klosek (Privacy); and partner Deborah Birnbach (Litigation).